To date, 3.3 million doses have been administered in Cuba for the benefit of 1.6 million children, who did not experience serious adverse events and whose immunological results were superior to those observed in adults.
The main researcher in the clinical trials on the vaccine developed by the Finlay Vaccines Institute, Maria Eugenia Toledo, claimed in relation to these studies that myocarditis or pericarditis was not observed in any minor.
The expert added that after the immunization was completed, no deceased children were reported in Cuba.
In addition to this event, Cuba’s Center for Genetic Engineering and Biotechnology (CIGB) disclosed recently that it is working on a study with the Abdala vaccine against Covid-19 in children under two years of age.
The Workshop on the scientific results of the Soberana Pediatrics clinical trials was held at the Hotel Nacional de Cuba.